Method for preparing genetically-modified T cells which express chimeric antigen receptor
In order to improve the efficiency of gene introduction in CAR therapy employing a transposon method, provided is a method for preparing genetically-modified T cells expressing chimeric antigen receptor, comprising: (1) a step of preparing non-proliferative cells which are obtained by stimulating a group of cells comprising T cells using an anti-CD3 antibody and an anti-CD28 antibody followed by a treatment for causing the cells to lose their proliferation capability; (2) a step of obtaining genetically-modified T cells into which a target antigen-specific chimeric antigen receptor gene has been introduced using a transposon method; (3) a step of mixing the non-proliferative cells prepared by step (1) with the genetically-modified T cells obtained by step (2), and co-culturing the mixed cells while stimulating the mixed cells using an anti-CD3 antibody and anti-CD28 antibody; and (4) a step of collecting the cells after culture.
1. A method for preparing genetically-modified T cells expressing chimeric antigen receptor, comprising the following steps (1) to (4):
(1) a step of preparing non-proliferative cells which are obtained by stimulating a group of cells comprising T cells using an anti-CD3 antibody and an anti-CD28 antibody followed by a treatment for causing the cells to lose their proliferation capability;
(2) a step of introducing a target antigen-specific chimeric antigen receptor gene into T cells using a transposon method and thereby obtaining the genetically-modified T cells;
(3) a step of mixing the non-proliferative cells prepared by step (1) with the genetically-modified T cells obtained by step (2), and co-culturing the mixed cells while stimulating the mixed cells using an anti-CD3 antibody and anti-CD28 antibody; and
(4) a step of collecting the cells after culture;
wherein the step (1) is conducted in advance of step (2);
wherein introducing the target antigen-specific chimeric antigen receptor gene into the T cells and mixing the genetically-modified T cells with the non-proliferative cells are conducted on the same day.
2. The preparation method according to claim 1 , wherein, after the cells are co-cultured, a step of culturing the co-cultured cells in the presence of a T-cell growth factor is carried out between step (3) and step (4).
3. The preparation method according to claim 1 , wherein the period of the co-culturing in step (3) is one day to 14 days.
4. The preparation method according to claim 1 , wherein step (3) is carried out in the presence of a T-cell growth factor.
5. The preparation method according to claim 4 , wherein the T-cell growth factor is IL-15.
6. The preparation method according to claim 4 , wherein the T-cell growth factor is a combination of IL-15 and IL-7.
7. The preparation method according to claim 1 , wherein the group of cells comprising T cells is peripheral blood mononuclear cells (PBMCs).
8. The preparation method according to claim 1 , wherein the treatment for losing the proliferation capability is irradiation.
9. The preparation method according to claim 1 , wherein the transposon method comprises preparing a vector including the gene coding transposase and a vector having a structure wherein the gene coding a target protein is sandwiched between inverted repeat sequences, and introducing these vectors to the target cell.
10. The preparation method according to claim 1 , wherein the target antigen is the CD19, GD2, GMCSF receptor or the IGF receptor.
11. The preparation method according to claim 1 , wherein the non-proliferative cells and the genetically-modified T cells are derived from an identical individual.